Article info

Original research
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

Authors

  • Maite Alvarez Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Carmen Molina Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Carlos E De Andrea Navarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, SpainPathology, Clinica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Myriam Fernandez-Sendin Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Maria Villalba Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, SpainPathology, Clinica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Jose Gonzalez-Gomariz Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Maria Carmen Ochoa Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Alvaro Teijeira Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Javier Glez-Vaz Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Fernando Aranda Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, Spain PubMed articlesGoogle scholar articles
  • Miguel F Sanmamed Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, SpainImmunology and Oncology, Clinica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Maria E Rodriguez-Ruiz Immunology and Oncology, Clinica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  • Xinyi Fan Radiation Oncology, Weill Cornell Medicine, New York, New York, USA PubMed articlesGoogle scholar articles
  • Wen H Shen Radiation Oncology, Weill Cornell Medicine, New York, New York, USA PubMed articlesGoogle scholar articles
  • Pedro Berraondo Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Marisol Quintero Oncology, Highlight Therapeutics, Valencia, Spain PubMed articlesGoogle scholar articles
  • Ignacio Melero Immunology and Immunotherapy, Center for Applied Medical Research (CIMA). University of Navarra, Pamplona, SpainNavarra Institute for Health Research (IdiSNA), Pamplona, SpainCentro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, SpainImmunology and Oncology, Clinica Universidad de Navarra, Pamplona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ignacio Melero; imelero{at}unav.es; Dr Maite Alvarez; malvarezr{at}unav.es
View Full Text

Citation

Alvarez M, Molina C, De Andrea CE, et al
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy

Publication history

  • Accepted September 28, 2021
  • First published November 25, 2021.
Online issue publication 
May 08, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.